FDA Approves Pfizer and BioNTech's Updated XFG-Variant COVID-19 Vaccine

Key Facts

1The U.S. FDA approved Pfizer and BioNTech's 2026-2027 COVID-19 vaccine formula targeting the XFG variant.

2The vaccine is approved for adults aged 65+ and high-risk individuals aged 5 to 64 years.

3Shipping will begin immediately for availability in U.S. pharmacies and hospitals in the coming days.

In a move that underscores the ongoing adaptation of public health measures, the U.S. FDA has approved Pfizer and BioNTech's updated COVID-19 vaccine for the 2026-2027 season, specifically targeting the XFG variant. The approval covers adults aged 65 and older, as well as high-risk individuals between the ages of 5 and 64. According to reports, shipping is scheduled to commence immediately to ensure the vaccine is available in U.S. pharmacies and hospitals in the coming days.

This regulatory milestone aligns vaccine compositions with contemporary circulating variants to maintain protection levels. Per market data, PFE shares closed at $28.3793 and BNTX shares closed at $112.12 (close of August 26, 2026). The approval reinforces the companies' position in the seasonal immunization market, utilizing their established mRNA platform to address evolving viral strains.

Looking ahead, the immediate distribution serves as a catalyst for upcoming quarterly revenue as the fall vaccination cycle begins. Based on market data from the August 26, 2026 session, PFE traded between a low of $28.145 and a high of $28.49, while BNTX saw a range between $111.215 and $113.97, reflecting investor focus on the commercial rollout of the updated formula.